June 21, 2013

Everolimus immunosuppression in de novo heart transplant recipients: What does the evidence tell us now?


Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177

Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177

Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177
.   .   

This review article analyzes the currently available data supporting the use of everolimus in de novo heart transplant patients. Rejection, renal function, malignancy, infection and wound complications including pleural and pericardial effusions are examined. The evidence suggests that the most convincing reasons for use of everolimus are to slow the progression of CAV and to lower the risk of cytomegalovirus infection.

Cardiac Transplantation

Tags: , , , , , ,